OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”). Each subscription right now entitles holders to purchase one unit (th ...

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The su ...

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen®, aimed at treating late-stage pancreatic cancer, with an expected gross proceeds of $12 million if fully subscribed [2][5]. Group 1: Rights Offering Details - The rights offering allows holders of the company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [3][4]. - Each unit consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock, with the preferred stock convertible into 833 shares of common stock at a conversion price of $1.20 per share [4]. - The subscription rights are non-transferable and must be exercised by 5:00 p.m. Eastern Time on February 27, 2026, unless extended by the company [6]. Group 2: Financial Implications - If the rights offering is fully subscribed, the company anticipates receiving aggregate gross proceeds of $12 million [5]. - Holders who fully exercise their basic subscription rights will have the opportunity to subscribe for additional units that remain unsubscribed due to unexercised basic subscription rights [5]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), which is a highly selective TLR3 agonist immuno-modulator showing promise in treating late-stage pancreatic cancer [12].

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][10] Rights Offering Details - The rights offering allows holders of the Company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [2][4] - Each subscription right entitles the holder to purchase one unit, which consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock [3] - The preferred stock is convertible into 833 shares of common stock at a conversion price of $1.20 per share, and each warrant is exercisable for one share of common stock at the same exercise price [3] Financial Projections - If fully subscribed, the rights offering is expected to generate gross proceeds of $12 million [4] - Holders who fully exercise their basic subscription rights can subscribe for additional units that remain unsubscribed [4] Subscription Period - The subscription period commenced on February 11, 2026, and will end on February 27, 2026, unless extended by the Company [5] - Subscription rights are non-transferable and must be exercised during the subscription period [5] Management and Regulatory Information - Maxim Group LLC has been engaged as the dealer-manager for the rights offering [6] - The offering is made pursuant to a registration statement declared effective by the SEC on February 10, 2026 [7]

Core Viewpoint - AIM ImmunoTech Inc. is conducting a rights offering to raise gross proceeds of $12 million for corporate purposes, including clinical trial expenses and debt repayment [1][4]. Rights Offering Details - The subscription rights are non-transferable and can be exercised from February 11, 2026, to February 27, 2026, unless extended [2][5]. - The rights offering includes an over-subscription privilege allowing holders to purchase additional unsubscribed shares, subject to pro-rata allocation if demand exceeds supply [2]. - AIM's leadership, including CEO Thomas K. Equels, has indicated a non-binding intention to participate in the rights offering [3]. Financial Use of Proceeds - The net proceeds from the rights offering will be allocated for general corporate purposes, specifically for clinical trial and manufacturing expenses related to Phase 2/3 pancreatic cancer trials, as well as repaying existing debt [4]. Important Dates - Key dates for the rights offering include: - February 9, 2026: Ownership Day for stockholder record [8] - February 10, 2026: Record Date [8] - February 11, 2026: Subscription Period Begins [8] - February 27, 2026: Subscription Period Ends [8] Registration and Compliance - A registration statement has been filed with the SEC but is not yet effective, meaning securities cannot be sold until it becomes effective [9]. - The rights offering will be conducted only through a written prospectus [9]. Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen® [11].

Core Viewpoint - AIM ImmunoTech Inc. is conducting a proposed rights offering to raise gross proceeds of $12 million, which will be used for general corporate purposes, including clinical trial expenses and debt repayment [1][5]. Rights Offering Details - The rights offering will provide one non-transferable subscription right for each share of common stock and certain options and warrants held as of the record date of February 4, 2026 [2]. - Each subscription right allows the purchase of one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock [2]. - The subscription rights are non-transferable and can be exercised from February 5, 2026, to February 23, 2026, unless extended by the company [3][6]. Leadership Participation - Certain members of AIM's leadership, including CEO Thomas K. Equels, have indicated a non-binding intention to participate in the rights offering [4]. Use of Proceeds - The net proceeds from the rights offering will be allocated for clinical trial expenses related to Phase 2/3 pancreatic cancer trials and to repay certain existing debt obligations [5]. Important Dates - Key dates for the rights offering include: - February 3, 2026: Ownership Day for stockholders of record - February 4, 2026: Record Date - February 5, 2026: Subscription Period Begins - February 23, 2026: Subscription Period Ends [7]. Information Distribution - Broadridge Corporate Issuer Solutions, LLC will mail rights certificates and a prospectus to holders of record starting on or about February 5, 2026 [8].

Core Insights - AIM ImmunoTech Inc. reported solid clinical and operational execution in Q3 2025, focusing on advancing Ampligen towards FDA approval for pancreatic cancer treatment [2] - Positive mid-year safety and efficacy data from the DURIPANC clinical trial combining Ampligen with AstraZeneca's Imfinzi were highlighted, with a year-end update expected [2] Financial Highlights - As of September 30, 2025, AIM reported cash, cash equivalents, and marketable investments of $2.4 million [8] - Research and development expenses for Q3 2025 were approximately $607,000, a decrease from $1.4 million in Q3 2024 [8] - General and administrative expenses were approximately $1.8 million for Q3 2025, down from $3.1 million in the same period of 2024 [8] - The net loss from operations for Q3 2025 was approximately $(3.3 million), or $(1.57) per share, compared to $(3.7 million), or $(6.00) per share, for Q3 2024 [8] - The company expects a monthly burn rate of approximately $550,000 while maintaining operational efficiencies [8]

Core Insights - AIM ImmunoTech Inc. is focusing on advancing clinical trials of Ampligen® for pancreatic cancer treatment, aiming for drug approval [2][4] - The company reported a bolstered cash position, with funding expected to last approximately 12 months following a public equity offering that raised $8.0 million [10] - Positive mid-year data from the Phase 2 clinical study of Ampligen® in combination with AstraZeneca's Imfinzi® shows no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) [2][10] Financial Highlights - AIM ImmunoTech closed a public equity offering, raising $8.0 million in gross proceeds [10] - The company has regained its listing status on the NYSE American [10] Clinical Development - The ongoing Phase 2 study (DURIPANC) evaluates Ampligen® combined with Imfinzi® for metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX [10] - The company has received U.S. and EU Orphan Drug designations for pancreatic cancer [10] Intellectual Property - AIM ImmunoTech has been granted U.S. patents covering methods of manufacturing therapeutic dsRNA, including Ampligen, and for its combination with PD-L1 drugs for cancer treatment [10] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® as its lead product [7]

Group 1 - AIM ImmunoTech Inc. announced the closing of a public offering of 2,000,000 shares of common stock and accompanying warrants at a combined public offering price of $4.00 per share, resulting in gross proceeds of approximately $8.0 million before expenses [1][2][3] - The offering included Class E and Class F warrants, both of which are exercisable immediately upon issuance, with Class E warrants expiring on the fifth anniversary and Class F warrants expiring on the eighteen-month anniversary of the original issuance date [1] - Maxim Group LLC acted as the sole placement agent for this offering [2] Group 2 - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug with broad-spectrum activity in clinical trials [4]

Core Viewpoint - AIM ImmunoTech Inc. has announced a public offering of 2,000,000 shares of common stock and accompanying warrants, aiming to raise approximately $8.0 million before expenses [1]. Group 1: Offering Details - The public offering includes 2,000,000 shares of common stock or pre-funded warrants, along with Class E and Class F warrants, each allowing the purchase of up to 2,000,000 shares [1]. - The combined public offering price is set at $4.00 per share or $3.999 per pre-funded warrant, with warrants exercisable immediately upon issuance [1]. - Class E warrants will expire five years after issuance, while Class F warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected around July 30, 2025, pending customary closing conditions [1]. Group 2: Financial and Regulatory Information - Gross proceeds from the offering are anticipated to be approximately $8.0 million before deducting placement agent fees and offering expenses [1]. - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on July 28, 2025 [3]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [5]. - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials [5].